Wolfe: 'Arrowhead Q3 data in acute pancreatitis will be the next big event to readthrough to Ionis. We see 74% odds of IONS stock down, 26% odds up'
Tweet Send to a Friend
Wolfe Research analyst Andy Chen reiterated an Outperform rating and $98.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
